Supplementary table 1. List of optimum variables for respiratory research, determined by the expert panel and presented to the Delphi participants in phase 2. The number and percentage of participant who considered the variable to be absolutely required/minimum variable for any asthma/COPD research are given. Dark grey fill indicates variables with >66% agreement, and lighter grey fill indicates variables with 50-66% agreement.

Survey Variable	No. of participants, n = 64	% of participants	
Demographics			
Date of birth	54	84.4	
Time of birth	1	1.6	
Details of birth	17	26.6	
Gender	57	89.1	
Nationality	25	39.1	
Ethnicity	44	68.8	
Marital status	20	31.3	
Number of dependents	10	15.6	
Number of people in household	26	40.6	
Level of education	37	57.8	
Socio-economic status	45	70.3	
Geographical location	32	50.0	
Salary range	13	20.3	
Health insurance coverage	25	39.1	
Place of birth	13	20.3	
Occupation/Working environment	46	71.9	
Family/Household income	29	45.3	
Height	44	68.8	
Weight	46	71.9	
Obesity	8	12.5	
Body Mass Index	34	53.1	
Alcohol use	35	54.7	
Illicit drug use	28	43.8	
Diet	23	35.9	
Smoking - current status	53	82.8	
Smoking - pack years	41	64.1	
Smoking - no. of cigarettes	28	43.8	
Smoking - years exposed	28	43.8	
Smoking - parental smoking	30	46.9	
Smoking - passive smoking	35	54.7	
Physical activity	40	62.5	
Blood testing			
Date of test	37	57.8	
Units	35	54.7	
Normal range	28	43.8	
Full blood count with differentiation	40	62.5	
Hemoglobin	26	40.6	
Creatinine	22	34.4	

Glomerular filtration rate	12	18.8
Liver function	15	23.4
C-reactive protein	24	37.5
Immunoglobulin E (total, specific)	38	59.4
Immunoglobulin G (total, specific)	12	18.8
Skin prick test	13	20.3
Dipeptidyl peptidose IV (DPPIV)	3	4.7
Serum periostin	4	6.3
Vitamin D	11	17.2
O2 saturation	24	37.5
Blood gases	16	25.0
Genetics/Genomic profiling	6	9.4
Fibrinogen, BNP, Troponin	9	14.1
Alpha-1-anti-trypsin	12	18.8
Serum MMP-7, KL6, SP-A, collagen degradation products	4	6.3
Lung markers	<u>'</u>	0.0
Date of lung function measurement	45	70.3
Forced Expiratory Volume in 1 second (FEV1)	42	65.6
Pre-broncodilator Forced Expiratory Volume in 1 second (FEV1-pre)	35	54.7
Post-broncodilator Forced Expiratory Volume in 1 second (FEV1-post)	37	57.8
Forced Expiratory Volume in 1 second % predicted (FEV1% pred)	32	50.0
Forced Vital Capacity (FVC)	41	64.1
Forced Vital Capacity % predicted (FVC%pred)	27	42.2
Peak Expiratory Flow (PEF)	21	32.8
Fraction of exhaled nitric oxide (FeNO)	21	32.8
Exhaled Breath Condensate	6	9.4
Bronchodilator response	19	29.7
Impulse oscillometry (IOS)	6	9.4
Bronchial Hyperreactivity (BHR)	10	15.6
Carbon monoxide (CO)	17	26.6
Diffusing capacity of the lungs for carbon monoxide (DLCO)	19	29.7
Carbon monoxide transfer coefficient (KCO)	12	18.8
Total Lung Capacity (TLC)	16	25.0
Broncho-Alveolar Lavage (BAL)	6	9.4
Poligraphy	5	7.8
Audio Assessment (e.g. assessment for lung crackles/Velcro)	5	7.8
Bronchoscopy	6	9.4
Bronchoscopy transbronchial lung biopsy	6	9.4
Exercise test (e.g. 6 minutes walk test)	19	29.7
Open Lung Biopsy (OLBx) [for Interstitial Lung Disease (ILD) patients]	8	12.5
Cough	28	43.8
Sputum	25	39.1
Imaging		
Date of imaging	37	57.8
Chest X-ray	32	50.0
High resolution computer tomography (HRCT)	20	31.3
MRI	7	10.9
PET	6	9.4

V/q scan	6	9.4
CT angiogram of the chest	6	9.4
Echocardiogram	13	20.3
CT scan of the thorax	13	20.3
Environmental Factors		
Outdoor air pollution	36	56.3
Indoor/household air pollution	40	62.5
Allergen exposures (mould, pets)	37	57.8
Occupational exposure	45	70.3
Secondhand smoke exposure	38	59.4
Healthcare Utilization		
Date of contact/contact (healthcare)	43	67.2
Primary Care Consultations	44	68.8
Reason for Primary Care Consultations	35	54.7
type of contacts (telephone, face-to-face, home visits)	15	23.4
Secondary Care Consultations	42	65.6
Reason for Secondary Care Consultations (e.g. for lower respiratory	32	50.0
complaints)	<u></u>	33.3
Unscheduled healthcare contacts	31	48.4
Hospitalisations/ Hospital admission	47	73.4
Hospital discharge date	18	28.1
Duration of hospitalisation	29	45.3
Reason for Hospitalisations/Hospital admission (e.e. for lower	42	65.6
respiratory complaints)		
A&E/ER attendances	39	60.9
Reason for A&E/ER attendances (e.g for lower respiratory complaint)	36	56.3
ICU Stay	37	57.8
Reason for ICU Stay (e.g pneumonia)	29	45.3
ICU duration	23	35.9
Out patient department attendance	24	37.5
Reason for outpatient department attendance (e.g. rehabilitation)	20	31.3
Rehabilitation	27	42.2
Duration of Rehabilitation	22	34.4
Physiotherapy	26	40.6
Reason for physiotherapy	17	26.6
Duration physiotherapy	16	25.0
Out of hours attendances	13	20.3
Personnel time	8	12.5
Cost of HRU	15	23.4
Treatments		
Generic drug name	39	60.9
Brand drug name	17	26.6
Prescribed Drug Name	24	37.5
Prescribed Drug Class	16	25.0
Date prescribed	33	51.6
Dispensed Drug Name	22	34.4
Dispensed Drug Class	13	20.3
Date Dispensed	24	37.5

Indication of use	23	35.9
Drug strength	29	45.3
Pack size	20	31.3
Frequency of Use/Prescribing instructions	36	56.3
Quantity of refill	20	31.3
Device (e.g. metered dose inhaler)	28	43.8
Spacer (e.g. aerochamber)	23	35.9
Inhaler technique	26	40.6
Over the counter medications	18	28.1
Self-management (or action) plan	28	43.8
Oxygen Usage (intermittent or chronic)	26	40.6
Peak flow metre (registration as part of patient management)	13	20.3
Adherence	29	45.3
CPAP	17	26.6
Non-invasive ventilation	17	26.6
Pneumococcal vaccination history	28	43.8
Influenza vaccination history	29	45.3
Coding system		
ATC (Anatomical Therapeutic Chemical)	22	34.4
Multilex	7	10.9
NDC (National Drug Code - often used in the US)	11	17.2
J-codes for office administered drugs (e.g. biologics)	7	10.9
RxNorm	10	15.6
ICD-9	6	9.4
ICD-10	26	40.6
ICD-11	15	23.4
ICPC	6	9.4
Read	5	7.8
SNOMED CT	12	18.8
Comorbidities		
Parental Atopy	17	26.6
Premature birth	18	28.1
Charlson Comorbidity Index	25	39.1
Date of disease diagnosis	25	39.1
Reported date	10	15.6
Resolved date	7	10.9
Status (active, resolved, other)	12	18.8
Diabetes Mellitus	34	53.1
Eczema	22	34.4
Rhinitis	33	51.6
Nasal Polyps	30	46.9
Osteoporosis	22	34.4
Psychiatric disorders	23	35.9
Depression/Anxiety	30	46.9
Gastroesophageal Reflux Disease	24	37.5
Chronic Kidney Disease	17	26.6
Lung Cancer	33	51.6
Sleep Apnoea	29	45.3

Anaemia	18	28.1
Cognitive Dysfunction	19	29.7
Cerebrovascular Disease	23	35.9
Bronchiectasis	32	50.0
Asthma	43	67.2
COPD	43	67.2
Asthma-COPD Overlap	31	48.4
Interstitial Lung Disease	27	42.2
Tuberculosis	37	57.8
HIV/AIDS	30	46.9
Cardiovascular Disease	36	56.3
Ischaemic Heart Disease	30	46.9
Hypertension	29	45.3
Heart Failure	31	48.4
Myocardial Infarction	26	40.6
Rheumatoid Arthritis	24	37.5
Nasal hyper-reactivity	11	17.2
Bronchial hyper-reactivity	12	18.8
Connective tissue disease and features suggestive of CTD	15	23.4
(Raynaud's phenomenon, Morning stiffness, digital oedema		
Sinusitis	23	35.9
Rhinosinusitis	26	40.6
Pneumonia	31	48.4
Osteoporosis	18	28.1
Other cancers besides lung	18	28.1
Mortality		
Mortality Status – Alive/Deceased	44	68.8
Cause of death	41	64.1
Primary cause of death	34	53.1
Secondary/contributing cause of death	27	42.2
Date of Death	42	65.6
Exacerbations		
Asthma Exacerbations	44	68.8
COPD Exacerbations	43	67.2
Interstitial lung disease exacerbations	29	45.3
Include other severe respiratory episodes (e.g. influenza, pneumonia)	33	51.6
Severity of exacerbations	31	48.4
CF exacerbations	21	32.8
Patient Reported Outcomes		
Asthma Symptom Utility Index (ASUI)	9	14.1
Asthma control questionnaire (ACQ)	32	50.0
(Children's) asthma control test (ACT)	25	39.1
Asthma bother profile (ABP)	4	6.3
(Pediatric) asthma related quality of life questionnaire (AQLQ)	11	17.2
Asthma impact survey (AIS-6)	7	10.9
COPD assessment test (CAT)	33	51.6
Clinical COPD Questionnaire (CCQ)	22	34.4
Saint Georges Respiratory Questionnaire (SGRQ)	21	32.8

Dyspnoea – Royal College of Physicians 3 Questions (RCP3)	11	17.2
EQ-5D	26	40.6
Sino-nasal outcome test (SNOT-22)	8	12.5
Rhinitis Control Assessment Test	6	9.4
Control of allergic rhinitis and asthma test (CARAT)	9	14.1
Hospital Anxiety depression (HADS)	16	25.0
(modified) Medical Research Council Dyspnea scale (MRC)	20	31.3
Short form health survey (SF-12)	13	20.3

Supplementary table 2. Number (and percentage) of participants in phase 3 who considered each variable as required for each type of study. Grey fill indicate variables with >66% agreement between participants.

	Asthma Retrospective	Asthma Prospective	COPD Retrospective	COPD Prospective
Demographics	Retrospective	Fiospective	Retrospective	Fiospective
Date of birth	32 (94.1)	33 (97.1)	32 (94.1)	33 (97.1)
Gender	34 (100)	34 (100)	34 (100)	34 (100)
Ethnicity	11 (32.4)	18 (52.9)	11 (32.4)	18 (52.9)
Level of education	9 (26.5)	16 (47.1)	9 (26.5)	16 (47.1)
Socio economic status	13 (38.2)	21 (61.8)	12 (35.3)	22 (64.7)
Geographical location	18 (52.9)	23 (67.6)	18 (52.9)	23 (67.6)
Coograpmean rocation	10 (02.0)	20 (01.10)	10 (02.0)	20 (01.10)
Clinical				
Height	19 (55.9)	28 (82.4)	18 (52.9)	28 (82.4)
Weight	14 (41.2)	14 (41.2)	14 (35.9)	24 (70.6)
Body Mass Index	21 (61.8)	24 (70.6)	20 (58.8)	23 (67.6)
Occupational environment	17 (50)	28 (82.4)	18 (52.9)	28 (82.4)
Alcohol use	4 (11.8)	8 (23.5)	4 (11.8)	8 (23.5)
Smoking status	29 (85.3)	32 (94.1)	29 (85.3)	32 (94.1)
Pack years	24 (70.6)	30 (88.2)	25 (73.5)	32 (94.1)
Passive smoking	13 (38.2)	22 (64.7)	13 (38.2)	23 (67.6)
Physical activity	6 (17.6)	19 (55.9)	8 (23.5)	20 (58.8)
•		, ,	,	, ,
Biomarkers				
Full blood count with	18 (52.9)	26 (76.5)	17 (50)	27 (79.4)
differentiation				
Immunoglobulin E	10 (29.4)	27 (79.4)	3 (8.8)	9 (26.5)
Lung function				
FEV1 prebronchodilation	15 (44.1)	25 (73.5)	17 (50)	24 (70.6)
FEV1 postbronchodilation	16 (47.1)	28 (82.4)	20 (58.8)	31 (91.2)
FEV1% predicted	21 (61.8)	26 (76.5)	23 (67.6)	28 (82.4)
FVC	19 (55.9)	25 (73.5)	21 (61.8)	28 (82.4)
Environmental factors				
Outdoor air pollution	6 (17.6)	12 (35.3)	8 (23.5)	13 (38.2)
Indoor air pollution	8 (23.5)	15 (44.1)	9 (26.5)	15 (44.1)
Allergen exposure	12 (35.3)	23 (67.6)	2 (5.9)	6 (17.6)
Occupational exposure	15 (44.1)	21 (61.8)	17 (50)	23 (67.6)
Secondhand smoke	11 (32.4)	19 (55.9)	12 (35.3)	19 (55.9)
Healthcare utilization				
Primary care consultation	25 (73.5)	27 (79.4)	25 (73.5)	27 (79.4)
Reason Primary Care Visit	14 (41.2)	23 (67.6)	14 (41.2)	23 (67.6)
Secondary care visit	20 (58.8)	25 (73.5)	21 (61.8)	24 (70.6)
Reason Secondary Care visit	11 (32.4)	19 (55.9)	11 (32.4)	19 (55.9)

Hospitalisation	30 (88.2)	31 (91.2)	30 (88.2)	31 (91.2)
Reason hospitalisation	20 (58.8)	26 (76.5)	20 (58.8)	26 (76.5)
ER admission	26 (76.5)	30 (88.2)	25 (73.5)	29 (85.3)
Reason ER admission	15 (44.1)	26 (76.5)	14 (41.2)	25 (73.5)
ICU stay	18 (52.9)	23 (67.6)	17 (50)	23 (67.6)
Chest X-ray	3 (8.8)	12 (35.3)	5 (14.7)	17 (50)
Medication				
Generic drug name	32 (94.1)	34 (100)	32 (94.1)	34 (100)
Date prescribed	20 (58.8)	22 (64.7)	20 (58.8)	22 (64.7)
Frequency of use	22 (64.7)	26 (76.5)	22 (64.7)	26 (76.5)
Comorbidities				
Diabetes Mellitus	18 (52.9)	18 (52.9)	24 (70.6)	27 (79.4)
Rhinitis	27 (79.4)	32 (94.1)	13 (38.2)	17 (50)
Lung cancer	14 (41.2)	15 (44.1)	27 (79.4)	32 (94.1)
Bronchiectasis	16 (47.1)	16 (47.1)	22 (64.7)	26 (76.5)
Asthma	21 (61.8)	21 (61.8)	32 (94.1)	34 (100)
COPD	30 (88.2)	31 (91.2)	22 (64.7)	22 (64.7)
TBC	14 (41.2)	14 (41.2)	19 (55.9)	22 (64.7)
Cardiovascular disease	15 (44.1)	16 (47.1)	27 (79.4)	30 (88.2)
Mortality				
Mortality	31 (91.2)	30 (88.2)	33 (97.1)	32 (94.1)
Cause of death	18 (52.9)	23 (67.6)	19 (55.9)	24 (70.6)
Primary Cause of death	19 (55.9)	28 (82.4)	20 (58.8)	29 (85.3)
Date of death	23 (67.6)	26 (76.5)	24 (70.6)	27 (79.4)
Exacerbations				
Asthma exacerbations	33 (97.1)	34 (100)	12 (35.3)	12 (35.3)
COPD exacerbations	12 (35.3)	11 (32.4)	33 (97.1)	34 (100)
Other severe respiratory episodes	21 (61.8)	25 (73.5)	21 (61.8)	27 (79.4)
Patient Reported Outcomes				
ACQ	19 (55.9)	34 (100)	2 (5.9)	4 (11.8)
CAT	2 (5.9)	5 (14.7)	19 (55.9)	34 (100)

ACQ: asthma control questionnaire; CAT: COPD Assessment Test; ER: emergency room; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; ICU: intensive care unit.